Pursuant to section 106(1) of the Medicines Act 1981, I, Dr Don Mackie, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health, acting under delegated authority, hereby declare the following:
- The medicines listed in Schedule 1 to this notice are classified as prescription medicines.
- The medicines listed in Schedule 2 to this notice are classified as restricted medicines.
- The medicines listed in Schedule 3 to this notice are classified as pharmacy-only medicines.
Every reference to a medicine in this notice applies whether the medicine is synthetic in origin or is from biological or mineral sources.
Unless specific reference is made otherwise, every reference applies also to medicines that are:
- preparations and admixtures containing any proportion of any substance listed in the notice.
- salts and esters of any substance listed in the notice.
- preparations or extracts of biological materials listed in the notice.
- salts or oxides of elements listed in the notice.
Unless specific reference is made otherwise, every reference to a medicine applies:
- if the medicine is in an injection or eye preparation, to any concentration of that medicine; and
- if the medicine is not in an injection or eye preparation, only if the concentration of the medicine is greater than 10 milligrams per litre or per kilogram.
Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol or element unless specifically stated otherwise.
Schedule 1
Prescription Medicines
Alectinib
Amifampridine
AOD-9604
Artesunate
Asunaprevir
Benzbromarone
Benzydamine; except for oromucosal or topical use
Cholic acid
CJC-1295
Daclatasvir
Defibrotide
Elbasvir
Felbamate
Flunarizine
Grazoprevir
Growth Hormone Releasing Peptide-6
Growth Hormone Releasing Hormones
Growth Hormone Releasing Peptides
Idebenone
Influenza vaccine; except when administered to a person 13 years of age or over by a registered pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health
Lesinurad
Levomilnacipran
Methylhexanamine (1,3-dimethylamylamine (DMAA)); except when present as an unmodified, naturally occurring medicine
Milnacipran
Naloxegol
Netupitant
Nitazoxanide
Nivolumab
Pentostatin
Ponatinib
Picibanil
Pralmorelin
Ranitidine; except when specified elsewhere in this schedule; except in medicines containing 300 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than seven days’ supply
Rufinamide
Sargramostim
Stiripentol
Steptozocin
Sunifiram
Tizanidine
Trientine
Ulipristal
Schedule 2
Restricted Medicines
Cyclizine; for oral use other than in medicines used for the treatment of anxiety or insomnia when sold in the manufacturer’s original pack containing not more than six dosage units; for oral use in medicines used for the treatment of anxiety or insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units
Schedule 3
Pharmacy-only Medicines
Ranitidine; in medicines for the symptomatic relief of heartburn, dyspepsia and hyperacidity or to be used on the recommendation of a registered medical practitioner when sold in the manufacturer’s original pack containing not more than 14 days’ supply; except in medicines containing 300 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than seven days’ supply
Medicines for General Sale
Please note that the following medicines are now available for general sale.
Benzydamine; for oromucosal or topical use
Ranitidine; in medicines containing 300 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than seven days’ supply
Dated this 22nd day of February 2016.
DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health.